Sugi Predict

Sugi Predict / Compounds / SCHEMBL2459618

SCHEMBL2459618

SCHEMBL2459618

CN1CCN(C(=O)C2CCC(C3=C4C=NC=C[N+]4(N)C(c4cccc(OCc5ccccc5)c4)=N3)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 6/20 0.46
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ TNK2 Q07912 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ TMEM97 Q5BJF2 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ESR2 Q92731 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ BTK Q06187 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459771 0.93 IGF1R (0.51) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2460493 0.93 IGF1R (0.52) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2459666 0.93 IGF1R (0.53) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2459610 0.93 IGF1R (0.53) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2463107 0.92 IGF1R (0.46) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2461612 0.91 IGF1R (0.46) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2456845 0.91 IGF1R (0.45) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2457081 0.89 IGF1R (0.44) IGF1RALDH1A1KDM4ELMNAHTT
SCHEMBL2460388 0.89 PRMT5 (0.41) IGF1RALDH1A1TNK2KMT2A
SCHEMBL2457647 0.88 IGF1R (0.46) IGF1RALDH1A1KDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 IGF1R 1/4885ALDH1A1 703/4885KDM4E 1461/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885ALDH1A1 703/4885KDM4E 1461/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885ALDH1A1 703/4885KDM4E 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.